Clinical observation of salvianolic acid B in treatment of liver fibrosis in chronic hepatitis B

Table 4 Serum HA, LM, IV-C and PIIIP contents before, during and after treatment

		HA (μg/L)	LM (μg/L)	IV-C (μg/L)	PIIIP (μg/L)
IFN-γ group	Before	250 ± 210	94 ± 27	112 ± 64	10.4 ± 5.0
	During	225 ± 248	110 ± 22	219 ± 143	10.2 ± 4.4
	After	185 ± 172	104 ± 26	212 ± 105	8.0 ± 2.8
SA-B group	Before	267 ± 211	103 ± 17	294 ± 155	13.2 ± 8.1
	During	219 ± 243	117 ± 21	248 ± 164	11.9 ± 4.9
	After	169 ± 183a	118 ± 24	190 ± 142bc	9.7 ± 5.3

^aP < 0.05,

^bP < 0.01, vs before treatment;

^cP < 0.05, vs during treatment.